Remembering a special friend and ISPE Boston Chapter member, Dan Rufo

Posted by ISPE Boston
On October 25, 2022

On October 7, 2022, our dear friend and long-time ISPE Boston member, Daniel J. Rufo, Jr. sadly passed away. We reached out to a few of our Chapter members who worked closely with Dan over the years to write short remembrances in celebration of Dan’s life, legacy, and impact on their lives, the Boston Chapter […]

Waters Announces First LEED-Certified Chemical Manufacturing Facility in MA

Posted by ISPE Boston
On October 25, 2022

Waters Corporation’s newly built Precision Chemical Manufacturing Facility in Taunton has achieved LEED certification. The products manufactured at this facility are essential for thousands of laboratories that ensure the quality and safety of medicines, food and water for millions of people worldwide. Waters’ Taunton site is the first and only LEED-certified chemical manufacturing facility in […]

A Beautiful Day for Fall Golf!

Posted by ISPE Boston
On October 25, 2022

Two weeks ago, we gathered at Indian Pond Country Club in Kingston, MA for the annual Fall Golf Tournament. This tournament is held annually to benefit the ISPE Boston Area Chapter Scholarship Foundation, which provides scholarships to students and career professionals alike, who are pursuing a degree in a STEM field in the New England […]

Ascidian Therapeutics Launches to Rewrite RNA

Posted by ISPE Boston
On October 20, 2022

Ascidian Therapeutics has launched with a $50 million Series A financing from life sciences venture capital firm ATP. With a focus on treating human diseases by replacing mutated exons at the RNA level, Ascidian’s technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. […]

Cambridge Biotechs Raise $$ for Precision Medicine

Posted by ISPE Boston
On October 20, 2022

Odyssey Therapeutics has raised $168 million in a Series B financing following its $218 million Series A in December 2021, bringing the total capital raised to $386 million. The funding will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines. “Odyssey is pioneering next generation therapeutics by marrying a powerful drug discovery […]

Game On! with Emerging Leaders

Posted by Tyler Haywood
On October 20, 2022

At the end of September, our Emerging Leaders Committee hosted a networking social at Game On! at Fenway Park, followed by the Red Sox vs. Orioles game on 9/28. Everyone gathered at Game On! to enjoy food, drinks, and laughs, before heading over to Fenway Park after the first pitch. The good times continued during […]

Thoughts From a Few of Our 2022 Scholarship Recipients!

Posted by ISPE Boston
On October 20, 2022

Congratulations to our 2022 Joel Goldenberg Memorial Scholarship recipients, Megan Fussell, Brooke DeSimone, and Dylan Miller! Here are their thoughts on being recipients of the scholarship this year: MEGAN FUSSELL – NORTHEASTERN UNIVERSITY, BIOTECHNOLOGY 1. Please describe how winning the Joel Goldenberg Memorial Scholarship(s) has helped your educational and/or career development. I am incredibly grateful […]

Palleon Co-Founder Awarded Nobel Prize in Chemistry

Posted by ISPE Boston
On October 7, 2022

Palleon Pharmaceuticals scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry. Waltham-based Palleon is a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases. The award reflects Dr. Bertozzi’s deep contributions not only to chemistry but to biology and medicine, including the foundational science underlying Palleon’s first-in-class, […]

FDA Approves Amylyx Drug to Treat ALS

Posted by ISPE Boston
On October 7, 2022

Cambridge-based Amylyx Pharmaceuticals has won FDA approval for Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease. Relyvrio significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. Relyvrio can be taken as a monotherapy or with existing approved treatments. ALS is […]

Biogen and Eisai Alzheimer’s Drug Shows Positive Results in Phase 3 Trial

Posted by ISPE Boston
On October 6, 2022

Partners Eisai and Biogen announced positive topline results from Eisai’s Phase 3 clinical trial of lecanemab, an investigational drug for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease. Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results. Eisai plans to discuss the data with regulatory authorities […]

Page 29 of 118«‹27 282930 31 ›»